Phathom Pharmaceuticals
PHAT
6.81
+0.03
+0.44%
Phathom Pharmaceuticals
US · PHAT
#3684 by market cap
Listed 2019
6.81
+0.03
+0.44%
Live - 5344 symbols - heartbeat 257s ago
· 2026-10-08 07:12
Pre-market
7.00
+2.79%
After-hours
6.80
-0.15%
- Market cap
- 550.94M
- P/E (TTM)i
- -5.45
- P/Bi
- -1.60
- EPSi
- -3.03
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on PHAT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.8 percentage points.
Institutional ownership
- Held by institutions
- 90.99% -2.81pp
- Institutions
- 195 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund38.92%
VC/PE Fund34.47%
Hedge Fund13.82%
Individual/Insider3.51%
Public Company2.74%
Private Company0.54%
Government Pension Fund0.21%
Insurance Company0.19%
Other5.52%
Top holders as of 2026-06-30
Frazier Life Sciences Management, LP
15.41% · 12.47M sh
Medicxi Ventures (UK) LLP
9.23% · 7.46M sh
BlackRock
5.59% · 4.53M sh
Invesco Ltd.
4.98% · 4.03M sh
Abingworth LLP
4.32% · 3.50M sh
Millennium Management LLC
4.17% · 3.38M sh
Vanguard Capital Management, LLC
3.72% · 3.01M sh
GW&K Investment Management, LLC
2.68% · 2.17M sh
Franklin Resources
2.44% · 1.97M sh
New Enterprise Associates, Inc.
2.42% · 1.96M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 32 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 15.41% |
| David Socks | Co-Founder | 1.51% |
| Azmi Nabulsi | Co-Founder & COO | 0.98% |
| Terrie Curran | Chief Executive Officer | 0.48% |
| Asit Parikh | Independent Director | 0.18% |
| Robert Breedlove | -- | 0.08% |
| Molly Henderson | Chief Financial & Business Officer | 0.08% |
| Frank Karbe | Independent Director | 0.07% |
| James Topper | Independent Director | 0.05% |
| Heidi Fields | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-02 | Robert Breedlove | -- | Sale to Issuer | -460 | $9.05 |
| 2026-07-13 | Robert Breedlove | -- | Sale to Issuer | -1,555 | $11.04 |
| 2026-05-21 | Asit Parikh | Independent Director | Other Acquisition | +28,000 | -- |
| 2026-05-21 | Asit Parikh | Independent Director | Other Disposition | -28,000 | -- |
| 2026-05-19 | Asit Parikh | Independent Director | Derivative Sale to Issuer | -17,500 | -- |
| 2026-05-19 | Asit Parikh | Independent Director | Derivative Exercise and Retained | +17,500 | $4.95 |
| 2026-05-18 | Michael Cola | Independent Interim Chairman of the Board | Other Acquisition | +24,122 | -- |
| 2026-05-18 | Heidi Fields | Independent Director | Other Acquisition | +24,122 | -- |
| 2026-05-18 | James Topper | Independent Director | Other Acquisition | +24,122 | -- |
| 2026-05-18 | Frank Karbe | Independent Director | Other Acquisition | +24,122 | -- |
| 2026-05-18 | Theodore Schroeder | Director | Other Acquisition | +24,122 | -- |
| 2026-05-18 | Asit Parikh | Independent Director | Other Acquisition | +24,122 | -- |
| 2026-05-18 | Mark Stenhouse | Independent Director | Other Acquisition | +24,122 | -- |
| 2026-03-09 | Asit Parikh | Independent Director | Other Acquisition | +40,000 | -- |
| 2026-03-09 | Asit Parikh | Independent Director | Other Disposition | -40,000 | -- |
| 2026-02-26 | Robert Breedlove | -- | Sale to Issuer | -1,378 | $12.56 |
| 2026-02-26 | Robert Breedlove | -- | Other Acquisition | +2,790 | -- |
| 2026-02-26 | Robert Breedlove | -- | Other Acquisition | +13,000 | -- |
| 2026-02-09 | Steven Basta | Chief Executive Officer | Sale to Issuer | -6,277 | $12.82 |
| 2026-02-09 | Steven Basta | Chief Executive Officer | Other Acquisition | +12,362 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:12:41 · For reference only, not investment advice and not tailored to your situation.